C urrent guidelines for the management of heart failure (HF) divide patients with HF into 2 categories: those with reduced ejection fraction (EF of ≤40%; HFrEF) and those with preserved ejection fraction (>40%; HFpEF). 1 It has been recognized that a subset of patients with HFpEF previously had HFrEF. 2 These patients with recovery or improvement in EF (HFiEF) may be clinically distinct from those with persistently preserved or reduced EF.
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In 2011, Punnoose et al 2 reported that nearly 70% of patients with symptomatic HFpEF had recovered from a previously low EF. These patients were clinically distinct from those with HFpEF and more similar to the HFrEF population from which they initially arose. Further studies found that HFiEF is associated with a better biomarker profile, quality of life, and event-free survival than continued HFrEF and HFpEF 3, 4 but still experience a significant number of HF hospitalizations, suggesting persistent HF risk. 3 In this post hoc analysis of the Valsartan Heart Failure Trial (Val-HeFT) 5 database, we characterized the subjects who had improved their EF during the first 12 months of follow-up, evaluated the independent correlates of EF improvement, and determined whether their all-cause mortality was substantially different from the subjects whose EF remained reduced.
Methods
Study Design and Patient Selection
Val-HeFT was a randomized, placebo-controlled, double-blind trial that enrolled 5010 patients with New York Heart Association functional class II to IV HF and an EF of <40% designed to evaluate the efficacy of valsartan. All-cause mortality was one of the 2 primary Val-HeFT end points 5 . Valsartan treatment did not exhibit a statistically significant effect on mortality, but stratification by baseline severity of left ventricular remodeling influenced the results. Patients with worse left ventricular internal diastolic diameter (LVIDd) and EF were at highest risk of an event and gained the most antiremodeling effect and clinical benefit with valsartan treatment. 6 Val-HeFT was approved by the institutional review board at each center, and all subjects provided a written informed consent. Heart Failure With Improved Ejection Fraction
Echocardiographic Measurements of Left Ventricular Performance
Echocardiography, both the recording and interpretation, was carried out at 291 multinational sites. Participation in the trial was dependent on meeting specific core laboratory standards for recording and reading of LVIDd from 2 dimensionally directed M-mode echocardiography, and EF was derived from LV volumes using the area-length method. 7 During the trial, quality control was monitored from random sampling of patient studies, and this was satisfactorily maintained. 8 Serial echocardiograms in 5010 patients were obtained at baseline before randomization and at 4, 12, 18, 24, and 30 months after randomization.
Biochemical Measurements
A complete blood cell count and measurements of serum albumin, uric acid, creatinine, and blood urea nitrogen were performed at a central laboratory with a commercially automated system at randomization and after 4, 6, 12, 18 , and 24 months. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease equation. 9 Other variables used in this analysis included neurohormones (B-type natriuretic peptide [IRMA Shionogi] and N-terminal probrain natriuretic peptide [ECLIA Elecsys 2010 analyzer, Roche Diagnostics]) measured by commercially available assays, 10 norepinephrine [high-performance liquid chromatography with electrochemical detection], 11 endothelin I, big endothelin, plasma renin activity and aldosterone [by radioimmunoassay], high-sensitivity troponin T, 12 high-sensitivity C-reactive protein, 13 galectin-3, 14 soluble ST2, 15 and growth-differentiating factor 15.
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Statistical Analysis
Distributions of continuous variables are described using means and SDs and categorical variables as proportions expressed as percentages. Highly skewed continuous distributions are described by the median and the interquartile range and were transformed using natural logarithms for regression analyses. Baseline characteristics of the HFiEF and continued HFrEF groups were compared using a t test, Rank-sum test or χ 2 test as appropriate for the level of measurement and distribution of the variable.
Stepwise forward and backward logistic regression with a P value <0.10 required for entry or removal was used to identify independent correlates of substantial improvements in EF forcing the baseline EF into the model to help control for the inverse relationship between baseline EF measurements and changes in EF. First, all 42 baseline variables described in Table 1 were tested along with an indicator of subjects in the United States. Then the baseline neurohormones and cardiac biomarkers listed in Table 2 that were measured in at least ACE indicates angiotensin-converting enzyme; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HFiEF, heart failure with improved ejection fraction; H/o, history of; HFrEF, heart failure with reduced ejection fraction; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; LVIDd/BSA, left ventricular internal diastolic dimension corrected for body surface area; NYHA, New York Heart Association; PND, paroxysmal nocturnal dyspnea; S3, third heart sound; and WBC, white blood cell. were tested for addition to the 7 independent correlates from Table 1 . These regression analyses were clustered by the study center to estimate robust SEs. Discrimination provided by the logistic regression model containing the independent correlates was examined by the estimated probabilities of being in the HFiEF group and the area under the receiver operating characteristic curve. Survival in the HFiEF and continued HFrEF groups after month 12 is compared using Kaplan-Meier curves and the log-rank test. Mortality rates per 100 person-years were calculated, and the incidence rate ratio was estimated using Poisson regression clustered by the study center. The group discrimination of times to death was assessed by Harrell C index. A P value of <0.05 was considered statistically significant without adjustment for the number of comparisons being made during these exploratory analyses of data from a randomized controlled clinical trial. All analyses were done using version 12.1 of Stata software.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Changes in Ejection Fraction
Of the 5010 patients enrolled into Val-HeFT, 4997 patients had an echocardiographic assessment of left ventricular EF at baseline. Of these, 4410 met our cohort inclusion criteria of a baseline EF of <35%. Of the 4410 patients, 3519 (80%) had a 12-month EF and were included in our analysis. Of these, 321 patients (9.1%) who had a 12-month EF of >40% constituted the subgroup of patients with HFiEF, and 3198 patients (90.9%) who had a 12-month EF of ≤40% constituted the subgroup of patients with HFrEF. The EF improved from 28.7±5.6% to 46.5±5.6% in the subgroup of patients with HFiEF and remained reduced (25.2±6.2% and 27.5±7.1%) in the comparison group. The 12-month changes in EF were 17.8±8.0% (range, 6%-42%) in the HFiEF group and 2.3±6.7% (range, −27 to 27) in the continued HFrEF group. A significant difference in changes in EF between the subgroups of patients with HFiEF and HFrEF was observed by 4 months after the baseline assessment (8.8±9.0% versus 2.3±6.5% respectively, P<0.001), indicating earlier changes in EF in the 2 subgroups of patients were consistent in their direction and magnitude.
Baseline Clinical Characteristics
Baseline demographic and clinical characteristics of the study groups with HFiEF and HFrEF are compared in Table 1 . Overall, the group with HFiEF had features of less severe HF with higher baseline left ventricular EF and lower baseline LVIDd normalized to body surface area (LVIDd/BSA). This group was marginally younger and less likely to be of male sex compared with the group with HFrEF. Fewer patients in the HFiEF group had an ischemic origin of HF. This group had a higher prevalence of hypertension but a similar prevalence of diabetes mellitus, atrial fibrillation, or chronic obstructive pulmonary disease. Apart from a higher systolic and diastolic blood pressure, subjects with HFiEF had a similar symptomatic profile in respect to orthopnea, edema, paroxysmal nocturnal dyspnea, third heart sound, jugular venous distention, pulmonary rales, heart rate, and prevalence of New York Heart Association class III or IV. Clinical chemistry variables were not different between the 2 groups except for better markers of renal function (creatinine, blood urea nitrogen, and glomerular filtration rate) and higher serum sodium and cholesterol levels in the HFiEF group. More subjects with HFiEF were treated with valsartan and a β-blocker, and fewer subjects with HFiEF were treated with a statin.
Neurohormones and Cardiac Biomarkers
Available baseline levels of plasma neurohormones and cardiac biomarkers in each of the HF category are presented in Table 2 . Overall, the HFiEF group had less severe neurohormonal activation. Plasma norepinephrine, plasma renin activity (PRA), endothelin I, big endothelin, B-type natriuretic peptide, and N-terminal probrain natriuretic peptide were significantly lower in the HFiEF group compared with the HFrEF group. Plasma aldosterone level was also lower in the HFiEF group, but the BNP indicates B-type natriuretic peptide; Gal-3, galectin-3; GDF growth-differentiating factor; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, highsensitivity troponin T; NT-proBNP, aminoterminal probrain natriuretic peptide; PRA, plasma renin activity; and sST2, soluble ST2.
*Because of skewed distribution, values are presented as median (Quartile 2-Quartile 3).
difference did not reach statistical significance. The HFiEF group was also characterized by lower levels of B-type natriuretic peptide and N-terminal probrain natriuretic peptide, high-sensitivity troponin T, growth-differentiating factor 15, and soluble ST2. There was also a trend toward a lower level of galectin-3 in the HFiEF group, but there was no difference in the levels of highsensitivity C-reactive protein between the 2 HF groups.
Independent Correlates of Recovery of Ejection Fraction
The stepwise forward and backward logistic regression analysis that forced the baseline EF into the model (n=3511) identified 7 variables that were independent correlates of HFiEF: male sex (odds ratio [OR], 0.69), ischemic pathogenesis (OR, 0.41), body mass index (OR, 0.96), diastolic blood pressure (OR, 1.01), LVIDd/BSA (OR, 0.5), β-blocker therapy at baseline (OR, 1.9), and treatment with valsartan (OR, 1.5). Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis or more dilated left ventricle had much lower odds of a substantial improvement in EF. In addition to these 7 variables, the following neurohormones were measured in a large subset of subjects (n=2380): B-type natriuretic peptide, norepinephrine, PRA, aldosterone, high-sensitivity C-reactive protein, detectable troponin, and level of hs-troponin T. Out of these variables, only a detectable hs-troponin T at baseline was independently associated with reduced odds of being in the HFiEF group (OR, 0.43). The median (interquartile range) of probabilities of being in the HFiEF group estimated using a logistic regression model with the 8 independent correlates were 0.15 (0.08-0.22) in the HFiEF group and 0.06 (0.03-0.10) in the continued HFrEF group. The area under the receiver operating characteristic curve was 0.76 (95% confidence interval, 0.72-0.79). Thus, these 8 baseline variables provided some discrimination of subjects who had a substantially improved EF >12 months of follow-up. However, only 3 subjects had >50% estimated likelihood of being in the HFiEF group.
Survival
The 3519 subjects who had baseline EF of <35% and a 12-month assessment of EF were followed for a maximum 
Discussion
In this Val-HeFT population, 9% of subjects with a baseline EF of <35% recovered their EF at 12 months. This group of subjects with HFiEF had a higher prevalence of hypertension, a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and they were treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin T at baseline had much lower odds of a substantial improvement in EF. Improvement of the EF to >40% was associated with a better survival compared with persistently reduced EF. Our data support HFiEF as a stratum of HFrEF with a more favorable outcome, which occurs in a minority of patients with HFrEF who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile and who are treated with a more intense HF medication regimen.
In our patient population, only 9% of subjects with a baseline EF of <35% recovered their EF to >40% at 12 months. This is close to 10% of patients with a baseline EF of <50%, who recovered their EF to ≥50% in the study by Basuray et al. 3 Our results are consistent with others in that, compared with HFrEF, subjects with HFiEF are younger, 2,3 with a lower prevalence of coronary artery disease, 2 a better renal function, 2,3 and a better biomarker and neurohormonal profile. 3 In contrast to other reports, 2,3 our subjects with HFiEF had a similar symptom profile compared with subjects with HFrEF and were more likely to be treated with a β-blocker, an agent known to improve EF and long-term survival in HFiEF. 17 New in this study are the findings that patients randomized to valsartan treatment had greater odds of being in the HFiEF group.
Our study identified 8 variables that were independent correlates of HFiEF: male sex, ischemic pathogenesis, body mass index, diastolic blood pressure, LVIDd/BSA, detectable hs-troponin T, β-blocker therapy at baseline, and treatment with valsartan. However, we could not determine why the EF improved. Although these variables may be useful to predict which patients are more likely to have improvement in EF, all the 8 independent correlates combined identified only a few subjects who had a high probability of improvement in EF. Their predictive performance needs to be confirmed in other patient populations.
Our results are consistent with others in that, compared with HFrEF, subjects with HFiEF have a better long-term Figure. Kaplan-Meier curves of time to death in patients with heart failure with reduced ejection fraction (HFrEF) and those with improved ejection fraction (HFiEF). Heart Failure With Improved Ejection Fraction survival. 3 Other studies showed better long-term outcomes in patients with HF who have had an improvement in EF. Cintron et al 18 assessed the prognostic value of serial changes in EF in patients with chronic HF in the V-HeFT (Vasodilator-Heart Failure Trial) and found a significant and proportionate relationship between the direction and magnitude of changes in EF over time and the 1-year mortality. Serial assessments of left ventricular dimensions and function in the Studies of Left Ventricular Dysfunction (SOLVD) 19 and Australia-New Zealand Carvedilol Heart Failure 20 echocardiographic substudies, the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF) magnetic resonance imaging substudy, 21 and the A-HeFT (African American Heart Failure Trial) 22 have also found an association between favorable changes in left ventricular dimensions and EF and improved clinical outcome produced by enalapril, carvedilol, metoprolol, or isosorbide dinitrate and hydralazine combination.
In the study by Cintron et al, 18 changes in EF of >5% from baseline at 6 months (V-HeFT I) and 12 months (V-HeFT II), irrespective of whether the follow-up EF reached a certain recovery level, were the strongest predictors of survival and remained significant even after adjustment for therapy and baseline EF. Although this is perhaps the only study that addressed and found a consistent proportionality between the degree of change in the EF and the subsequent change in mortality, it suggests that any substantial improvement in EF is associated with an improvement in survival.
Several available publications have defined the subset of patients with HFpEF who previously had HFrEF as heart failure with recovered ejection fraction 2, 3, 17 or heart failure with better ejection fraction 4, 23 and have been using different EF cut-off points for defining this HF category (≥40%, 2 ≥45%, 17 and ≥50%
3,4
). In this article, we used the definition of heart failure with improved ejection fraction with the cut-off point of >40%, consistent with the current guideline for the management of heart failure. 1 We chose to truncate the population by analyzing only patients whose baseline EF was <35%, rather than including the entire Val-HeFT population with an EF of <40% because we wanted to identify a group that clearly had an improved EF to >40%. Given the error in measurement of EF, we felt a clear improvement in EF should be at least 5%.
Strengths and Limitations
We used well-characterized patients in the Val-HeFT trial where outcomes were adjudicated. In addition, we were able to examine EF improvement along with several established prognostic variables, including troponin and N-terminal probrain natriuretic peptide. The use of β-blockers and mineralocorticoid receptor antagonists was lower in the Val-HeFT population compared with that seen in contemporary clinical trials as was the absence of cardiac resynchronization therapy in the Val-HeFT population. Because these therapies strongly affect reverse remodeling and recovery of systolic function, these might influence the proportion of patients with improved EF and the overall impact of our results. In addition, we were not able to present the data on whether the patients who entered this study were on target doses of β-blockers or angiotensinconverting enzyme inhibitors and for how long. Although we found only 9% of patients with a baseline EF of <35% who had a 12-month EF of >40%, this probably underestimated the true proportion of patients with systolic dysfunction who got to the recovered state because the patients who entered this study have already been on optimal HF therapy. When individuals are recruited into new trials while on background therapy and there is an EF eligibility criterion, eligible patients will predominantly be nonresponders to standard therapy and with a poor prognosis. Thus, the patients entered into the new trials may not be adequately representative of HF seen in clinical practice. Val-HeFT enrolled patients with an EF of <40%. We excluded ≈12% of the Val-HeFT subjects who did not have a baseline EF of <35% and ≈18% who did not have a 12-month EF. Thus, our findings do not represent the entire Val-HeFT cohort. Although we report several state-of-practice statistical indices for evaluating prediction models, the individual predicted probabilities and predicted event-free survival curves that are most directly applicable to clinical practice ignore the uncertainty in the estimates as is often done when prediction models are used in clinical practice.
Conclusions
In this sample of patients with chronic HF, a minority of subjects with a baseline EF of <35% improved their EF to >40% at 12 months. This group of subjects with HFiEF had a higher prevalence of hypertension, a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and they were treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin T at baseline had much lower odds of a substantial improvement in EF. Improvement in the EF was associated with a better survival compared with persistently reduced EF. Our data support HFiEF as a stratum of HFrEF with a less severe hemodynamic, biomarker, and neurohormonal profile, who are treated with a more intense HF medication regimen, and who experience a more favorable change in LV function and long-term survival. However, additional studies are needed to determine whether HFiEF represents enduring recovery or a separate HF clinical entity that could be treated differently.
CLINICAL PERSPECTIVE
Current guidelines for the management of heart failure (HF) divide patients with HF into 2 categories: those with reduced ejection fraction (EF of ≤40%) and those with preserved EF (>40%; HFpEF). It has been recognized that a subset of patients with HFpEF previously had heart failure with reduced ejection fraction. These patients with recovery or improvement in EF may be clinically distinct from those with persistently preserved or reduced EF. The authors performed a post hoc analysis of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT) and identified 3519 subjects who had echocardiographic assessment of EF at both baseline and 12-month follow-up. In this sample of patients with chronic HF, a minority of subjects (9%) with a baseline EF of <35% improved their EF to >40% at 12 months. This group of subjects with HF with improved EF had a higher prevalence of hypertension, a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and they were treated with a more intense HF medication regimen. Improvement in EF was associated with a better survival compared with persistently reduced EF. The authors propose HF with improved ejection fraction as a stratum of HF with reduced ejection fraction with a less severe hemodynamic, biomarker, and neurohormonal profile, who are treated with a more intense HF medication regimen, and who experience a more favorable change in LV function and long-term survival. Additional studies are needed to determine whether HF with improved ejection fraction represents enduring recovery or a separate HF clinical entity that could be treated differently.
